- Home
- ESNT vs BDTX Comparison
ESNT vs BDTX Comparison
Compare ESNT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESNT | BDTX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 220.3M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ESNT | BDTX |
|---|---|---|
| Price | $64.38 | $2.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $66.80 | $10.60 |
| AVG Volume (30 Days) | 561.4K | ★ 1.8M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.87 | 0.38 |
| Revenue | ★ $1,263,558,000.00 | $70,000,000.00 |
| Revenue This Year | $3.87 | N/A |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | $9.35 | ★ $7.38 |
| Revenue Growth | ★ 2.04 | N/A |
| 52 Week Low | $51.61 | $1.20 |
| 52 Week High | $65.90 | $4.94 |
Technical Indicators
Market Signals| Indicator | ESNT | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.96 | 33.76 |
| Support Level | $61.25 | $2.61 |
| Resistance Level | $62.35 | $2.87 |
| Average True Range (ATR) | 0.98 | 0.26 |
| MACD | 0.20 | -0.08 |
| Stochastic Oscillator | 85.08 | 33.82 |
Price Performance
Historical ComparisonAbout ESNT Essent Group Ltd.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.